Dr. Leospace
Alpiniste Kundalini
- Inscrit
- 28/10/05
- Messages
- 686
WASHINGTON -- Seventeen years after it was withdrawn from U.S. markets, a synthetic version of the active ingredient in marijuana is going back on sale as a prescription treatment for the vomiting and nausea that often accompanies chemotherapy, its manufacturer said Tuesday.
Valeant Pharmaceuticals International hopes to begin selling Cesamet in the next two to three weeks, company president Wes Wheeler said.
The Costa Mesa, Calif. company received Food and Drug Administration approval Monday to resume sales of the drug, which it bought from Eli Lilly and Co. in 2004. Lilly originally received FDA approval for nabilone in 1985 but withdrew it from the market in 1989 for commercial reasons, Wheeler said Marinol, another synthetic version of tetrahydrocannabinol, the active ingredient in marijuana that's more commonly known as THC, is made by Belgium-based Solvay SA. It also received FDA approval in 1985.
Cesamet is a Schedule II drug, meaning it has a high potential for abuse. The FDA last month said it does not support the use of marijuana for medical purposes.
Source: Long Beach Press-Telegram (CA)
Valeant Pharmaceuticals International hopes to begin selling Cesamet in the next two to three weeks, company president Wes Wheeler said.
The Costa Mesa, Calif. company received Food and Drug Administration approval Monday to resume sales of the drug, which it bought from Eli Lilly and Co. in 2004. Lilly originally received FDA approval for nabilone in 1985 but withdrew it from the market in 1989 for commercial reasons, Wheeler said Marinol, another synthetic version of tetrahydrocannabinol, the active ingredient in marijuana that's more commonly known as THC, is made by Belgium-based Solvay SA. It also received FDA approval in 1985.
Cesamet is a Schedule II drug, meaning it has a high potential for abuse. The FDA last month said it does not support the use of marijuana for medical purposes.
Source: Long Beach Press-Telegram (CA)